RÉSUMÉ
BACKGROUND AND PURPOSE: We have recently demonstrated that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected. The objective of the study was to analyse differences in breast cancer treatment between screen-detected and non-screen-detected cases by age at diagnosis, with and without adjustment for tumour (T) and nodal (N) status, within a nationwide, population-based mammography screening programme utilising register data. MATERIAL AND METHODS: Data spanning 2008-2017 were collected from the National Quality Register for Breast Cancer. Multivariable logistic regression analysis was used to estimate odds ratios and 95% confidence intervals for treatment disparities between screen-detected and non-screen-detected breast cancer. RESULTS: Among 46,481 women diagnosed with invasive breast cancer aged 40-74 and invited for mammography screening, significant differences in treatment were observed. Screen-detected cases showed higher likelihoods of partial mastectomy compared to mastectomy, endocrine therapy, and radiotherapy, whereas chemotherapy and antibody therapy were less likely compared to non-screen-detected cases. However, when adjusting for surgery type, screen-detected cases showed lower likelihoods of radiotherapy. Age at diagnosis significantly influenced treatment odds ratios, with interactions observed for all treatments except radiotherapy adjusted for surgery. Differences increased with age, except for endocrine therapy. Radiotherapy adjusted for surgery type showed no age-related interaction. Adjusting for T and N did not alter these patterns. INTERPRETATION: In general, screen-detected cases received less aggressive treatment, such as mastectomy, chemotherapy, and antibody therapy, compared to non-screen-detected cases. Disparities increased with age, except for endocrine therapy and radiotherapy adjusted for surgery. Differences persisted after adjusting for T and N, suggesting that these factors cannot solely explain the results.
Sujet(s)
Tumeurs du sein , Dépistage précoce du cancer , Mammographie , Humains , Femelle , Tumeurs du sein/thérapie , Tumeurs du sein/diagnostic , Tumeurs du sein/anatomopathologie , Tumeurs du sein/épidémiologie , Adulte d'âge moyen , Suède/épidémiologie , Sujet âgé , Adulte , Mammographie/statistiques et données numériques , Dépistage précoce du cancer/statistiques et données numériques , Facteurs âges , Mastectomie/statistiques et données numériques , Enregistrements , Disparités d'accès aux soins/statistiques et données numériquesRÉSUMÉ
PURPOSE: Asian American, Native Hawaiian, and Pacific Islander (AANHPI) patient populations are often defined as one monolithic group in medical research despite cultural, socioeconomic, and clinical heterogeneity. Although the general AANHPI population is underrepresented in reception of postmastectomy breast reconstruction, existing literature has not characterized the disaggregation of such rates for AANHPI ethnic subgroups. METHODS: Patients who underwent mastectomy were identified in the 2007 to 2020 registries within the Surveillance, Epidemiology and End Results database. Patients were stratified by race and ethnicity, and additional demographic and oncologic variables were collected. Multivariate binary logistic regression was conducted to assess for reception of postmastectomy immediate breast reconstruction (p < 0.05). RESULTS: Among 33,422 AANHPI patients who underwent mastectomy, South Asian patients were associated with the highest breast reconstruction rates (33%) and Melanesians with the lowest (15%). Overall, AANHPI patients were associated with a lower breast reconstruction rate than non-Hispanic Whites (27% vs. 35%; p < 0.001). This difference increased from 6.4% in 2007 to 10% in 2020. After controlling for demographic and oncologic covariates, all AANHPI ethnic subgroups predicted a lower likelihood of breast reconstruction than non-Hispanic Whites (p < 0.001). Odds ratios for reconstruction ranged from 0.17 [95% confidence interval (95% CI), 0.11-0.27] for Melanesian patients to 0.45 (95% CI, 0.42-0.48) for South Asian patients. CONCLUSIONS: Disparities in the receipt of immediate breast reconstruction exist within the AANHPI patient population in the United States. This analysis supported the need for disaggregation in plastic surgery research for improved knowledge and targeted interventions.
Sujet(s)
, Tumeurs du sein , Mammoplastie , Mastectomie , Hawaïen autochtone ou autre insulaire du Pacifique , Adulte , Sujet âgé , Femelle , Humains , Adulte d'âge moyen , /statistiques et données numériques , Tumeurs du sein/chirurgie , Tumeurs du sein/ethnologie , Mammoplastie/statistiques et données numériques , Mastectomie/statistiques et données numériques , Hawaïen autochtone ou autre insulaire du Pacifique/statistiques et données numériques , Programme SEER , États-UnisRÉSUMÉ
BACKGROUND: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. This study aims to explore the features of Chinese MBC patients comprehensively. METHODS: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients. RESULTS: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %-88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175). CONCLUSION: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
Sujet(s)
Tumeur du sein de l'homme , Mastectomie , Biopsie de noeud lymphatique sentinelle , Humains , Tumeur du sein de l'homme/anatomopathologie , Tumeur du sein de l'homme/mortalité , Tumeur du sein de l'homme/thérapie , Tumeur du sein de l'homme/épidémiologie , Mâle , Adulte d'âge moyen , Chine/épidémiologie , Études rétrospectives , Mastectomie/statistiques et données numériques , Sujet âgé , Biopsie de noeud lymphatique sentinelle/statistiques et données numériques , Adulte , Pronostic , Modèles des risques proportionnels , Estimation de Kaplan-Meier , Taxoïdes/usage thérapeutique , Taux de survie , Composés pontés/usage thérapeutique , Anthracyclines/usage thérapeutique , Sujet âgé de 80 ans ou plusRÉSUMÉ
PURPOSE: This study was designed to characterize features of rapid relapse TNBC (rrTNBC), an aggressive, poor prognosis breast cancer subset using the National Cancer Database (NCDB). METHODS: Patients diagnosed with TNBC between 2010 and 2019 within NCDB were included in analyses. rrTNBC was defined as all-cause mortality ≤24 months from diagnosis. Patient demographic, tumor, and treatment association with rrTNBC were evaluated in univariate, bivariate analyses, and multiple logistic regression models. Two-part models are used to compare receipt of treatment (i.e., receipt of both chemotherapy and breast surgery) versus not in its relationship with rrTNBC. RESULTS: Overall, 14.5% of patients were categorized as rrTNBC. Age older than 75 years (-41.3%), Black race (-1.4%), Medicare (-2.6%), and Charlson-Deyo score ≥2 (-4.9%) were associated with a lower probability of receiving both chemotherapy and breast surgery. Not receiving both treatments (vs. receiving both chemotherapy and breast surgery) was associated with a two-to-three-fold higher probability of rrTNBC among patients aged older than 75 years (16.6% vs. 6%), having Medicare (3.6% vs. 1.6%), and Charlson-Deyo score ≥2 (16.6% vs. 5.9%). CONCLUSIONS: Age, insurance, and comorbidity were related to a lower likelihood of treatment; yet receiving treatment reduced the risk of rrTNBC threefold for each. These findings might be valuable to inform clinical care delivery, as well as future research that examines treatment protocols among diverse patients.
Sujet(s)
Bases de données factuelles , Récidive tumorale locale , Tumeurs du sein triple-négatives , Humains , Femelle , Sujet âgé , Récidive tumorale locale/anatomopathologie , Récidive tumorale locale/thérapie , Récidive tumorale locale/épidémiologie , Adulte d'âge moyen , États-Unis/épidémiologie , Tumeurs du sein triple-négatives/thérapie , Tumeurs du sein triple-négatives/anatomopathologie , Disparités d'accès aux soins/statistiques et données numériques , Taux de survie , Études de suivi , Pronostic , Mastectomie/statistiques et données numériques , Facteurs de risque , Medicare (USA)/statistiques et données numériques , Facteurs âges , Sujet âgé de 80 ans ou plus , AdulteRÉSUMÉ
BACKGROUND: The coronavirus-19 (COVID-19) pandemic caused delays in the diagnosis and management of breast cancer which may have affected disease presentation. The aim of this study was to compare rates of metastatic disease, tumour characteristics and management in breast cancer patients diagnosed before and after the onset of COVID-19. METHODS: A retrospective chart review was conducted on patients in a university teaching hospital who were diagnosed with invasive symptomatic breast cancer in 2019 (prepandemic control group) and in 2020, 2021, and 2022 (pandemic study groups). Rates of new metastatic presentations, tumour histopathological characteristics, operation type, and therapies administered were statistically compared. RESULTS: A total of 1416 patients were identified. There was a significant increase in new metastatic breast cancer presentations in 2022 compared to 2019 (14.0% vs 3.8%, p ≤ 0.001), with non-significant increases in 2020 and 2021. Rates of adjuvant radiotherapy increased in 2020 and decreased in 2022 compared to 2019, with no significant change in neoadjuvant or adjuvant chemotherapy rates. Rates of axillary surgery increased during 2020 and 2021. There was an increase in high-grade tumours and lymphovascular invasion (LVI), and less frequent oestrogen receptor (ER) positivity in pandemic groups. No significant change was noted in BCS to mastectomy ratios, overall nodal positivity rates, or median tumour size. CONCLUSION: Symptomatic breast cancers diagnosed since the onset of COVID-19 demonstrated an increase in new metastatic presentations and more aggressive histopathological characteristics when compared to a pre-pandemic control group. Rates of adjuvant radiotherapy and axillary surgery increased during the pandemic.
Sujet(s)
Tumeurs du sein , COVID-19 , Humains , COVID-19/épidémiologie , Tumeurs du sein/anatomopathologie , Tumeurs du sein/thérapie , Tumeurs du sein/épidémiologie , Femelle , Études rétrospectives , Adulte d'âge moyen , Irlande/épidémiologie , Sujet âgé , SARS-CoV-2 , Adulte , Pandémies , Mastectomie/statistiques et données numériques , Radiothérapie adjuvante/statistiques et données numériques , Traitement médicamenteux adjuvant/statistiques et données numériquesRÉSUMÉ
PURPOSE: There has been a UK national directive to ensure that patients are offered reconstructive surgical options. We aimed to assess any change in oncoplastic practice over a 10-year period. METHODS: The surgical management of 7019 breast cancers was retrospectively assessed at Nightingale Breast Centre, Manchester University UK, from 2010 to 2019. The procedures were categorised into breast conservative surgery (BCS) and mastectomy ± immediate reconstruction. The data were analysed using inclusion and exclusion criteria. RESULTS: The overall rates of BCS and mastectomy were 60.1% and 39.9% respectively. No statistically significant change in the overall rates of BCS or mastectomy was observed over the last decade (p = 0.08). The rate of simple wide local excision (WLE) decreased from 98.7% to 89.3% (p < 0.001), whilst the rate of therapeutic mammoplasty (TM) increased from 1.3% to 8% (p < 0.01). The rate of chest wall perforator flaps (CWPF) changed from zero to account for 2.7% of all BCS by 2019. The overall rate of immediate breast reconstruction (IBR) did not significantly change over the study period, but it consistently remained above the national average of 27%. The rate of implant-based IBR increased from 61.3% to 76.5% (p = 0.012), whilst the rate of Latissimus Dorsi (LD) reconstruction decreased from 26.7% to 5.1% (p < 0.05). Additionally, the rate of nipple-sparing mastectomy significantly increased from 5.2% to 24%. CONCLUSION: No significant changes in the overall rates of BCS was observed, the rates of advanced breast conservation techniques, nipple-sparing mastectomy, and implant-based IBR all have increased, whilst the use of LD reconstruction decreased.
Sujet(s)
Tumeurs du sein , Mammoplastie , Mastectomie , Humains , Femelle , Mammoplastie/tendances , Mammoplastie/méthodes , Mammoplastie/statistiques et données numériques , Tumeurs du sein/chirurgie , Tumeurs du sein/anatomopathologie , Tumeurs du sein/épidémiologie , Études rétrospectives , Adulte d'âge moyen , Mastectomie/méthodes , Mastectomie/statistiques et données numériques , Mastectomie/tendances , Adulte , Sujet âgé , Mastectomie partielle/méthodes , Mastectomie partielle/statistiques et données numériques , Royaume-Uni/épidémiologieRÉSUMÉ
INTRODUCTION: Breast cancer (BC) incidence has been increasing among Asian-Americans (AsAms); recent data suggest these patients are less likely to undergo postmastectomy breast reconstruction (PMBR) compared to non-Asian women. Historically, AsAm BC patients are reported in aggregate, masking heterogeneity within this population. We aim to identify patterns of postmastectomy reconstruction among disaggregated AsAm BC patients at our institution. METHODS: A retrospective chart review was performed for BC patients who underwent mastectomy between 2017 and 2021. Patient demographic and clinical information was collected including self-reported race/ethnicity and reconstruction at time of mastectomy. Self-identified Asian patients were disaggregated into East Asian, Southeast Asian, South Asian, and 'Asian Other.' We examined rates of reconstruction between the different races and the disaggregated Asian subgroups. Univariable and multivariable analysis was performed to examine patient factors associated with PMBR. RESULTS: Six hundred and five patients met inclusion criteria. Forty seven percent of patients identified as Asian, 36% of which as East Asian. Forty four percent of all patients underwent PMBR. Southeast Asian and South Asian women were least likely to undergo reconstruction, while Hispanic and non-Hispanic Black women were most likely to pursue PMBR (P = 0.020). On multivariable analysis, Hispanic, non-Hispanic White, and non-Hispanic Black women were more likely to undergo reconstruction compared to Asian women. Other factors associated with reconstruction were coverage with private insurance and diagnosis of noninvasive disease. CONCLUSIONS: Rates of PMBR are lower among AsAms than non-Asian patients and vary between Asian ethnic subgroups. Further investigation is needed to identify patterns of reconstruction among the disaggregated AsAm population to address disparities.
Sujet(s)
, Tumeurs du sein , Disparités d'accès aux soins , Mammoplastie , Mastectomie , Humains , Femelle , Tumeurs du sein/chirurgie , Tumeurs du sein/ethnologie , Mammoplastie/statistiques et données numériques , /statistiques et données numériques , Études rétrospectives , Adulte d'âge moyen , Mastectomie/statistiques et données numériques , Adulte , Sujet âgé , Disparités d'accès aux soins/statistiques et données numériques , Disparités d'accès aux soins/ethnologieRÉSUMÉ
BACKGROUND: Breast cancer is the most common cancer affecting females in Canada, and about half of females with breast cancer are treated with mastectomy. We sought to evaluate geographic variation in breast reconstruction surgery in Alberta, Canada. METHODS: Using linked population-based administrative databases, we extracted data on all Alberta females aged 18 years and older who were diagnosed with breast cancer and treated with mastectomy during 2004-2017. Analyses included regression modelling of odds of reconstruction at 1 year and a spatial scan to identify geographic clusters of lower numbers of reconstruction. RESULTS: A total of 16 198 females diagnosed with breast cancer were treated with a mastectomy, and 1932 (11.9%) had reconstruction within 1 year postmastectomy. Those with reconstruction were more likely to be younger (adjusted odds ratio [OR] 16.7, 95% confidence interval [CI] 13.7-20.3; aged 21-44 yr v. ≥ 65 yr) and were less likely to be from lower-income neighbourhoods. They were more likely to have at least 1 comorbidity and were more likely to have advanced stages of cancer and to require chemotherapy (adjusted OR 0.55, 95% CI 0.47-0.65) or radiotherapy after mastectomy (adjusted OR 0.59, 95% CI 0.39-0.87) than females without reconstruction. We identified rural northern and southeastern clusters with frequencies of reconstruction that were 69.6% and 41.6% of what was expected, respectively. CONCLUSION: We found an overall postmastectomy rate of breast reconstruction of 11.9%, and we identified geographic variation. Predictors of reconstruction in Alberta were similar to those previously described in the literature, specifically with patients in rural communities having lower rates of reconstruction than their urban counterparts. These results suggest that further interventions are required to identify the specific barriers to reconstruction within rural communities and to create strategies to ensure equitable access to all residents.
Sujet(s)
Tumeurs du sein , Mammoplastie , Mastectomie , Humains , Femelle , Alberta/épidémiologie , Tumeurs du sein/chirurgie , Tumeurs du sein/épidémiologie , Mastectomie/statistiques et données numériques , Adulte , Adulte d'âge moyen , Mammoplastie/statistiques et données numériques , Sujet âgé , Jeune adulteRÉSUMÉ
PURPOSE: Postmastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and improves overall survival (OS) in patients with breast cancer. Young age has been recognized as a risk factor for LRR. The primary objective of this study was to determine if recommendations for PMRT differed among patients younger than 50 years as compared to women aged 50 years or older. METHODS: We reviewed medical records of patients with breast cancer who underwent mastectomy with or without PMRT from 2010 through 2018. Univariable and multivariable models were used to estimate the association of age with PMRT. RESULTS: Of 2471 patients, 839 (34%) were <50 years; 1632 (66%) were ≥50 years. Patients <50 years had a higher percentage of grade 3 tumors, hormone receptor (HR) negative and/or Her-2/neu positive tumors, clinical stage T2/T3 tumors, and nodal involvement. Compared with patients ≥50 years, patients <50 years were more likely to undergo PMRT (OR 1.57; P = .001) and regional node irradiation (RNI) to the internal mammary nodes. Advanced clinical and pathologic stage, invasive tumor histology, the presence of lymphovascular invasion, and treatment with systemic chemotherapy were predictors of PMRT receipt for patients <50 years (P < .05). PMRT was associated with improved OS and recurrence free survival (RFS) among all patients (P < .01). CONCLUSION: Patients <50 years were more likely to undergo PMRT and to receive RNI to the internal mammary nodes but were also more likely to have other risk factors for recurrence that would warrant a PMRT recommendation. PMRT improved OS and RFS for all patients.
Sujet(s)
Tumeurs du sein , Mastectomie , Récidive tumorale locale , Humains , Femelle , Tumeurs du sein/radiothérapie , Tumeurs du sein/anatomopathologie , Tumeurs du sein/chirurgie , Tumeurs du sein/mortalité , Adulte d'âge moyen , Mastectomie/statistiques et données numériques , Facteurs âges , Radiothérapie adjuvante/statistiques et données numériques , Récidive tumorale locale/épidémiologie , Récidive tumorale locale/anatomopathologie , Récidive tumorale locale/prévention et contrôle , Adulte , Sujet âgé , Études rétrospectives , Stadification tumorale , Facteurs de risqueRÉSUMÉ
BACKGROUND: Women with early breast cancer who meet guideline-based criteria should be offered breast conserving surgery (BCS) with adjuvant radiotherapy as an alternative to mastectomy. New Zealand (NZ) has documented ethnic disparities in screening access and in breast cancer treatment pathways. This study aimed to determine whether, among BCS-eligible women, rates of receipt of mastectomy or radiotherapy differed by ethnicity and other factors. METHODS: The study assessed management of women with early breast cancer (ductal carcinoma in situ [DCIS] and invasive stages I-IIIA) registered between 2010 and 2015, extracted from the recently consolidated New Zealand Breast Cancer Registry (now Te Rehita Mate Utaetae NZBCF National Breast Cancer Register). Specific criteria were applied to determine women eligible for BCS. Uni- and multivariable analyses were undertaken to examine differences by demographic and clinicopathological factors with a primary focus on ethnicity (Maori, Pacific, Asian, and Other; the latter is defined as NZ European, Other European, and Middle Eastern Latin American and African). RESULTS: Overall 22.2% of 5520 BCS-eligible women were treated with mastectomy, and 91.1% of 3807 women who undertook BCS received adjuvant radiotherapy (93.5% for invasive cancer, and 78.3% for DCIS). Asian ethnicity was associated with a higher mastectomy rate in the invasive cancer group (OR 2.18; 95%CI 1.72-2.75), compared to Other ethnicity, along with older age, symptomatic diagnosis, advanced stage, larger tumour, HER2-positive, and hormone receptor-negative groups. Pacific ethnicity was associated with a lower adjuvant radiotherapy rate, compared to Other ethnicity, in both invasive and DCIS groups, along with older age, symptomatic diagnosis, and lower grade tumour in the invasive group. Both mastectomy and adjuvant radiotherapy rates decreased over time. For those who did not receive radiotherapy, non-referral by a clinician was the most common documented reason (8%), followed by patient decline after being referred (5%). CONCLUSION: Rates of radiotherapy use are high by international standards. Further research is required to understand differences by ethnicity in both rates of mastectomy and lower rates of radiotherapy after BCS for Pacific women, and the reasons for non-referral by clinicians.
Sujet(s)
Tumeurs du sein , Mastectomie partielle , Radiothérapie adjuvante , Femelle , Humains , Tumeurs du sein/épidémiologie , Tumeurs du sein/ethnologie , Tumeurs du sein/radiothérapie , Tumeurs du sein/chirurgie , Carcinome intracanalaire non infiltrant/épidémiologie , Carcinome intracanalaire non infiltrant/ethnologie , Carcinome intracanalaire non infiltrant/radiothérapie , Carcinome intracanalaire non infiltrant/chirurgie , Maoris/statistiques et données numériques , Mastectomie/statistiques et données numériques , Mastectomie partielle/statistiques et données numériques , Nouvelle-Zélande/épidémiologie , Radiothérapie adjuvante/statistiques et données numériques , Population originaire des îles du Pacifique/statistiques et données numériques , /statistiques et données numériques , Européens/statistiques et données numériques , Populations du Moyen-Orient/statistiques et données numériques , Africains/statistiques et données numériquesRÉSUMÉ
INTRODUCTION: Studies have shown a decrease in bilateral mastectomy (BM) rates over the past five to ten years, but it is not clear if these decreases are the same across different patient races. METHODS: Using the National Cancer Database (NCDB) we examined BM rates for patients with AJCC Stage 0-II unilateral breast cancer from 2004 to 2020 for White versus nonwhite races (Blacks, Hispanics, and Asians). Multivariable logistic regression was used to identify patient and facility factors associated with BM by patient race from 2004 to 2006 and 2018-2020. RESULTS: Of 1,187,864 patients, 791,594 (66.6%) had breast conserving surgery (BCS), 258,588 (21.8%) had unilateral mastectomy (UM) and 137,682 (11.6%) had BM. Our patient population was 927,530 (78.1%) White patients, 124,636 (10.5%) Black patients, 68,048 (5.7%) Hispanic patients, and 48,341 (4.1%) Asian patients. The BM rate steadily increased from 5.6% to 15.6% from 2004 to 2013, at which point the BM rate decreased to 11.3% in 2020. The decrease in BM was seen across all races, and in 2020, 6,487 (11.7%) Whites underwent BM compared to 506 (10.7%) Hispanics, 331 (9.2%) Asians, and 723 (9.1%) Blacks. Race was a significant independent factor for BM in 2004-2006 and 2018-2020 but all races were more likely to undergo BM in 2004 compared to 2020 after adjusting for patient and facility factors. Compared to Whites, the odds of undergoing BM were OR 0.41 (0.37-0.45) in 2004 compared to OR 0.66 (0.63-0.69) in 2020 for Blacks, OR 0.44 (0.38-0.52) and OR 0.61 (0.57-0.65) for Asians and OR 0.59 (0.52-0.66) and OR 0.71 (0.67-0.75) for Hispanics, respectively. CONCLUSION: BM rates for all races have declined since 2013, and differences in rates of BM amongst races have narrowed.
Sujet(s)
Tumeurs du sein , Mastectomie , Femelle , Humains , Tumeurs du sein/chirurgie , Hispanique ou Latino , Mastectomie/statistiques et données numériques , Mastectomie partielle/statistiques et données numériques , , , BlancRÉSUMÉ
Aims: The clinical significance of nonvisualized sentinel lymph nodes (non-vSLNs) is unknown. The authors sought to determine the incidence of non-vSLNs on lymphoscintigraphy, the identification rate during surgery, factors associated with non-vSLNs and related axillary management. Patients & methods: A total of 30,508 consecutive SLN procedures performed at a single institution from 2000 to 2017 were retrospectively studied. Associations between clinicopathological factors and the identification of SLNs during surgery were assessed. Results: Non-vSLN occurred in 525 of the procedures (1.7%). In 73.3%, at least one SLN was identified intraoperatively. Nodal involvement was only significantly associated with SLN nonidentification (p < 0.001). Conclusion: Patients with non-vSLN had an increased risk for SLN metastasis. The detection rate during surgery was consistent, reducing the amount of unnecessary axillary dissection.
Lay abstract To study the clinical significance of nonvisualized sentinel lymph nodes (non-vSLNs) in axillary surgery for breast cancer, 30,508 consecutive SLN procedures performed at a single institution from 2000 to 2017 were retrospectively reviewed with the aim to analyze the incidence of non-vSLNs on lymphoscintigraphy, the identification rate during surgery, factors associated with non-vSLNs and related axillary management. Associations between clinicopathological factors and the identification of SLNs during surgery were assessed. Non-vSLN occurred in 525 of the procedures (1.7%). In 73.3%, at least one SLN was identified intraoperatively. Nodal involvement was only significantly associated with SLN nonidentification (p < 0.001). Patients with non-vSLN had an increased risk for SLN metastasis. The detection rate during surgery was consistent, reducing the amount of unnecessary axillary dissection.
Sujet(s)
Tumeurs du sein/anatomopathologie , Métastase lymphatique/diagnostic , Lymphoscintigraphie/statistiques et données numériques , Mastectomie/statistiques et données numériques , Sujet âgé , Aisselle , Tumeurs du sein/diagnostic , Tumeurs du sein/chirurgie , Femelle , Humains , Incidence , Période peropératoire , Métastase lymphatique/anatomopathologie , Adulte d'âge moyen , Stadification tumorale , Pronostic , Études rétrospectives , Noeud lymphatique sentinelle/imagerie diagnostique , Noeud lymphatique sentinelle/anatomopathologie , Biopsie de noeud lymphatique sentinelle/statistiques et données numériquesRÉSUMÉ
BACKGROUND: The infection rates for operative management of breast cancer are often unpredictable and higher than average for a clean surgical procedure (0.8% and 28%). We aimed to assess the effectiveness of the American College of Surgeons (ACS) Surgical Risk Calculator (SRC), a preoperative scoring system to calculate the risk of surgical site infection (SSI) and serious complications following breast surgery. METHODS: Prospective risk scoring using the SRC on 213 patients in the preoperative clinic and the incidence of SSI and serious complications within 30 days postoperatively was prospectively collected. RESULTS: The overall SSI rate in our sample was 5% (n=11/210 patients). For a one-unit increase in SRC score, the odds of having SSI increased by a factor of 1.88 (95% CI 1.33 to 2.74). Odds of developing SSI were higher in patients with high Body Mass Index (OR 1.25; 95% 1.13 to 1.40) and American Society of Anesthesiologists score 3 (OR 11.54; 95% CI 2.98 to 43.65). The odds of developing an SSI were â¼19 times higher if a patient had an SRC score >3.0 versus those with an SRC score <3.0. Only 3% (n=4) of patients who had an SRC score of <3.0 experienced SSI, compared with 33% (n=7) for those with a risk score of >3.0. Out of 210 patients, 9 had serious complications (4.2%). CONCLUSIONS: ACS SRC Score of more than 3 was associated with a higher likelihood of SSI. SRC was able to predict the risk of SSI and serious complications and can be used preoperatively for identification and risk minimisation.
Sujet(s)
Tumeurs du sein/chirurgie , Mastectomie , Infection de plaie opératoire/épidémiologie , Sujet âgé , Femelle , Humains , Mastectomie/effets indésirables , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Complications postopératoires/épidémiologie , Études prospectives , Facteurs de risqueRÉSUMÉ
BACKGROUND: During the COVID-19 pandemic, guidelines recommended that breast cancer centers delay estrogen receptor-positive breast cancer surgeries with neoadjuvant endocrine therapy. We aimed to evaluate pathologic upstaging of breast cancer patients affected by these guidelines. METHODS: Female patients with stage I/II breast cancer receiving neoadjuvant endocrine therapy were prospectively identified and were matched to a historical cohort of stage I/II estrogen receptor-positive breast cancer patients treated with upfront surgery ≤35 days. Primary outcomes were pathologic T and N upstaging versus clinical staging. RESULTS: After matching, 28 neoadjuvant endocrine therapy and 48 control patients remained. Median age in each group was 65 (P = .68). Most patients (78.6% and 79.2%) had invasive ductal carcinoma with a clinical tumor size of 0.9 cm vs 1.7 cm (P = .056). Time to surgery was 68 days in the neoadjuvant endocrine therapy group and 26.5 days in the control (P < .001). A total of 23 neoadjuvant endocrine therapy patients (82.1%) had the same or lower pT-stage compared with 31 (64.5%) control patients (P = .115). Only 3 (10.7%) neoadjuvant endocrine therapy patients had increased pN-stage vs 14 (29.2%) control patients (P = .063). CONCLUSION: Despite 2.5-times longer delays, patients with early-stage estrogen receptor-positive breast cancer receiving neoadjuvant endocrine therapy did not experience pathologic upstaging during the COVID-19 pandemic. These findings may support the use of neoadjuvant endocrine therapy in similar patients if delays to surgery are projected.
Sujet(s)
Antinéoplasiques hormonaux/usage thérapeutique , Tumeurs du sein/chirurgie , COVID-19 , Carcinome canalaire du sein/chirurgie , Délai jusqu'au traitement/statistiques et données numériques , Sujet âgé , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/métabolisme , Carcinome canalaire du sein/traitement médicamenteux , Carcinome canalaire du sein/métabolisme , Études cas-témoins , Femelle , Humains , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Traitement néoadjuvant , Études prospectives , Récepteurs des oestrogènes/métabolismeRÉSUMÉ
BACKGROUND: We sought to identify characteristics of metastatic breast cancer (MBC) patients who may benefit most from primary tumor resection. METHODS: Recursive partitioning analysis (RPA) was used to categorize non-surgical patients with de novo MBC in the NCDB (2010-2015) into 3 groups (I/II/III) based on 3-year overall survival (OS). After bootstrapping (BS), group-level profiles were applied, and the association of surgery with OS was estimated using Cox proportional hazards models. RESULTS: All patients benefitted from surgery (median OS, surgery vs no surgery): 72.7 vs 42.9 months, 47.3 vs 30.4 months, 23.8 vs 14.4 months (all p < 0.001) in BS-groups I, II, and III, respectively. After adjustment, surgery remained associated with improved OS (HR 0.52, 95% CI 0.50-0.55). The effect of surgery on OS differed quantitatively across groups. CONCLUSION: Prognostic groups may inform the degree of benefit from surgery, with the greatest benefit seen in those with the most favorable survival.
Sujet(s)
Tumeurs du sein/chirurgie , Mastectomie/statistiques et données numériques , Sélection de patients , Adulte , Sujet âgé , Tumeurs du sein/diagnostic , Tumeurs du sein/mortalité , Tumeurs du sein/anatomopathologie , Prise de décision clinique/méthodes , Femelle , Études de suivi , Humains , Estimation de Kaplan-Meier , Adulte d'âge moyen , Stadification tumorale , Pronostic , Modèles des risques proportionnels , Études rétrospectives , Appréciation des risques/méthodes , Appréciation des risques/statistiques et données numériques , Résultat thérapeutiqueRÉSUMÉ
OBJECTIVE: The use of autologous fat grafting in the context of breast reconstruction is still a matter of controversy. The objective of this study was to compare the local relapse rate in women who had a fat grafting session in the context of breast reconstruction after breast cancer management, to those who had breast reconstruction without fat grafting. METHODS: We performed a retrospective, monocentric, case-control study from January 2007 to December 2017 in our hospital. The cases included women who underwent breast reconstruction with autologous fat grafting and controls, undergoing breast reconstruction without fat grafting. We compared survival and local recurrence between the two groups. RESULTS: 412 women were included: 109 (26.5%) in the lipofilling group and 303 women (73.5%) in the "no lipofilling" group. In the overall study population, lipofilling did not appear to be a predictive factor for recurrence, HR = 1.39 [0.63 - 3.06], p = 0.41; or a predictive factor for overall survival, HR = 0.84 [0.23 - 3.02], p = 0.79, or for distant metastases, HR = 1.10 [0.43 - 2.79], p = 0.84. In contrast, in the subgroup of women treated for invasive cancer, the multivariate analysis showed that lipofilling in this context was an independent predictive factor for local recurrence (HR= 5.06 [1.97 - 10.6], p = 0.04). CONCLUSION: we found an increased risk of local recurrence after lipofilling in women who were managed for invasive breast cancer. This suggests that special consideration should be given to women who have had invasive breast cancer before lipofilling.
Sujet(s)
Tissu adipeux/chirurgie , Mammoplastie/normes , Adulte , Sujet âgé , Tumeurs du sein/complications , Tumeurs du sein/chirurgie , Études cas-témoins , Femelle , Humains , Mammoplastie/méthodes , Mammoplastie/statistiques et données numériques , Mastectomie/effets indésirables , Mastectomie/méthodes , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Études rétrospectives , Statistique non paramétrique , Transplantation autologue/méthodes , Transplantation autologue/normes , Transplantation autologue/statistiques et données numériquesRÉSUMÉ
BACKGROUND: When borderline axillary lymph nodes (bALN) are identified on ultrasound (US) for breast cancer (BC) patients, preoperative management is unclear. We aimed to evaluate if core needle biopsy (CNB) for bALN is clinically helpful or disruptive. METHODS: Retrospective review of BC patients with bALN from 2014 to 2019 was performed. Clinicopathologic data were compared for those who did and did not have CNB. RESULTS: CNB (n = 34) and no CNB (n = 31) were similar with respect to clinicopathologic factors. Surgical LN-positive rate was the same between cohorts (p = 0.26). CNB was disruptive in 58.8 %; all had CNB for pN0 disease. CNB was helpful in 34.2 %: 14.7 % proceeded directly to axillary dissection; 17.6 % had positive LN localized after neoadjuvant chemotherapy. CONCLUSIONS: CNB for bALN is more likely clinically disruptive and did not impact surgical LN positive rate. BC patients with bALN should undergo CNB only if it will change clinical management.
Sujet(s)
Tumeurs du sein/diagnostic , Carcinome canalaire du sein/diagnostic , Carcinome intracanalaire non infiltrant/diagnostic , Métastase lymphatique/diagnostic , Soins préopératoires/méthodes , Adulte , Sujet âgé , Aisselle , Biopsie au trocart/méthodes , Biopsie au trocart/statistiques et données numériques , Tumeurs du sein/anatomopathologie , Tumeurs du sein/thérapie , Carcinome canalaire du sein/anatomopathologie , Carcinome canalaire du sein/thérapie , Carcinome intracanalaire non infiltrant/anatomopathologie , Carcinome intracanalaire non infiltrant/thérapie , Traitement médicamenteux adjuvant , Prise de décision clinique/méthodes , Femelle , Humains , Biopsie guidée par l'image/méthodes , Biopsie guidée par l'image/statistiques et données numériques , Lymphadénectomie/statistiques et données numériques , Noeuds lymphatiques/imagerie diagnostique , Noeuds lymphatiques/anatomopathologie , Métastase lymphatique/anatomopathologie , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Traitement néoadjuvant , Soins préopératoires/statistiques et données numériques , Études rétrospectives , Sensibilité et spécificité , Biopsie de noeud lymphatique sentinelle/méthodes , Biopsie de noeud lymphatique sentinelle/statistiques et données numériques , Échographie interventionnelleRÉSUMÉ
BACKGROUND: Although breast cancer is the most common cancer among Sri Lankan women, there is little published data on patient characteristics and treatment in the local context. We aimed to describe disease characteristics and management in a large contemporary cohort of women with breast cancer at the National Cancer Institute of Sri Lanka (NCISL). METHODS: All women with invasive primary breast cancers diagnosed during 2016-2020 were identified from the NCISL breast cancer registry. The NCISL sees approximately 40% of all cancer patients in Sri Lanka. Cancer stage at diagnosis was defined according to the Tumour, Node, and Metastasis (TNM) staging system and the Estrogen (ER) and progesterone (PR) receptor status was determined based on the results of immunohistochemistry tests. Descriptive statistics were used to describe the study cohort and treatment patterns. RESULTS: Over 5100 patients were diagnosed with breast cancer during the study period at the NCISL. The mean age of the women was 56 (SD 12) years. Common co-morbidities were hypertension (n = 1566, 30%) and diabetes mellitus (n = 1196, 23%). Two thirds (66%) of the cancers were early stage (stage I & II) at diagnosis. ER/PR positivity rate was 72% and HER-2 positivity rate was 22%. Two thirds of the women had undergone mastectomy while 68% had undergone axillary clearance. The rate of chemotherapy delivery was 91% for women with node positive disease while 77% of eligible women (i.e., after wide local excision or with > 3 positive lymph nodes) had received adjuvant radiotherapy. Endocrine therapy was initiated in 88% of eligible women with hormone receptor positive disease while rate of trastuzumab use was 59% among women with HER2 positive breast cancer. CONCLUSIONS: High percentage of advanced breast cancer at diagnosis and high prevalence of comorbidities are some of the major challenges faced in the management of breast cancer in Sri Lanka. Given that stage at diagnosis is the most important prognostic factor determining survival, greater efforts are needed to promote early diagnosis of breast cancer. Considerable lapses in the concordance between guideline recommendations and the delivery of cancer care warrants closer assessment and intervention.
Sujet(s)
Tumeurs du sein/thérapie , Adulte , Répartition par âge , Sujet âgé , Sujet âgé de 80 ans ou plus , Antinéoplasiques/usage thérapeutique , Antinéoplasiques immunologiques/usage thérapeutique , Aisselle , Tumeurs du sein/composition chimique , Tumeurs du sein/épidémiologie , Tumeurs du sein/anatomopathologie , Carcinome canalaire du sein/épidémiologie , Carcinome lobulaire/épidémiologie , Traitement médicamenteux adjuvant/statistiques et données numériques , Comorbidité , Diabète/épidémiologie , Femelle , Humains , Hypertension artérielle/épidémiologie , Lymphadénectomie/statistiques et données numériques , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Radiothérapie adjuvante/statistiques et données numériques , Enregistrements , Sri Lanka/épidémiologie , Trastuzumab/usage thérapeutique , Résultat thérapeutique , Jeune adulteRÉSUMÉ
ABSTRACT: It is necessary to elucidate the potential risk factors of pulmonary infection to provide references for the management of breast cancer.Our study was a retrospective design, patients who underwent modified radical mastectomy for breast cancer in our department of breast surgery from January 2019 to November 2020 were included. The personal and clinical data of included patients with and without pulmonary infection were compared.A total of 234 patients with radical mastectomy were included, the incidence of pulmonary infection was 15.38% with 95%confidence interval (CI) 11.42% to 18.98%. There were significant differences in the age, body mass index, diabetes, duration of surgery, combined radiotherapy and chemotherapy, and duration of drainage between patients with and without pulmonary infections (all Pâ<â.05). Logistic regression analysis indicated that age ≥55âyears (odds ratio [OR] 2.128, 95%CI 1.105-3.426), body mass indexâ≥â24âkg/m2(OR 2.344, 95%CI 1.031-3.299), diabetes (OR 2.835, 95%CI 1.132-4.552), duration of surgery ≥120 minutes (OR 1.394, 95%CI 1.012-1.044), combined radiotherapy and chemotherapy (OR 3.122, 95%CI 1.124-5.273), duration of drainage ≥5âdays (OR 1.851, 95%CI 1.112-2.045) might be the independent risk factors of pulmonary infection in patients after radical mastectomy(all Pâ<â.05). Pseudomonas aeruginosa and Klebsiella pneumoniae are the most commonly seen bacteria.The incidence of postoperative pulmonary infections in breast cancer patients is high, and there are many associated risk factors. The perioperative management of patients should be strengthened targeted on those risk factors in clinical practice.
Sujet(s)
Tumeurs du sein/complications , Complications postopératoires/prévention et contrôle , Infections de l'appareil respiratoire/prévention et contrôle , Adulte , Indice de masse corporelle , Tumeurs du sein/chirurgie , Femelle , Humains , Incidence , Mastectomie/effets indésirables , Mastectomie/méthodes , Mastectomie/statistiques et données numériques , Adulte d'âge moyen , Odds ratio , Complications postopératoires/étiologie , Infections de l'appareil respiratoire/étiologie , Études rétrospectives , Facteurs de risqueRÉSUMÉ
BACKGROUND: Although immediate breast reconstruction is increasingly becoming popular worldwide, evidence from resource-limited settings is scarce. We investigated factors associated with immediate breast reconstruction in a multiethnic, middle-income Asian setting. Short-term surgical complications, timing of initiation of chemotherapy, and survival outcomes were compared between women undergoing mastectomy alone and their counterparts receiving immediate breast reconstruction. METHODS: This historical cohort study included women who underwent mastectomy after diagnosis with stage 0 to stage IIIa breast cancer from 2011 to 2015 in a tertiary hospital. Multivariable regression analyses were used to assess factors associated with immediate breast reconstruction and to measure clinical outcomes. RESULT: Out of 790 patients with early breast cancer who had undergone mastectomy, only 68 (8.6%) received immediate breast reconstruction. Immediate breast reconstruction was independently associated with younger age at diagnosis, recent calendar years, Chinese ethnicity, higher education level, and invasive ductal carcinomas. Although immediate breast reconstruction was associated with a higher risk of short-term local surgical complications (adjusted odds ratio: 3.58 [95% confidence interval 1.75-7.30]), there were no significant differences in terms of delay in initiation of chemotherapy, 5-year disease-free survival, and 5-year overall survival between both groups in the multivariable analyses. CONCLUSION: Although associated with short-term surgical complications, immediate breast reconstruction after mastectomy does not appear to be associated with delays in initiation of chemotherapy, recurrence, or mortality after breast cancer. These findings are valuable in facilitating shared surgical decision-making, improving access to immediate breast reconstruction, and setting priorities for surgical trainings in middle-income settings.